Epirium Bio
CA - SacramentoBiotechnology
Focus: Epirium Bio is a mitochondria-targeting biotech founded in 2008, currently in Series A stage with a focus on oncology therapeutics. The company operates as a pre-revenue biotech with a highly specialized platform.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Total Funding
$85M
Open Jobs
0
About Epirium Bio
AI assessmentNot HiringNo open roles listed right now. Follow Epirium Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Becker Muscular DystrophyClinical Trials (1)
NCT04386304Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Phase 1Help build intelligence for Epirium Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.